Phase I study of the combination of sorafenib and radiation therapy -/+ temozolomide for the treatment of patients with brain metastases and primary brain tumors.
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2016
At a glance
- Drugs Sorafenib (Primary) ; Temozolomide
- Indications Brain metastases; CNS cancer; Glioma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 17 Nov 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 28 Mar 2014 Planned End Date changed from 1 Mar 2013 to 1 Mar 2015 as reported by ClinicalTrials.gov.